SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03787446

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Positron Emission Tomography (PET) Imaging Study in Relapsing-Remitting and Primary-Progressive Multiple Sclerosis (MS): Correlations With Advanced MRI in MS

While both conventional and advanced MRI techniques offer important insights into MS pathophysiology, important aspects of this inflammatory disorder are undetectable with existing MRI technology. In Multiple Sclerosis (MS), there is growing interest in PET as an imaging modality that can increase the investigator's understanding of the disease processes and may add to an understanding of MS phenotype, particularly when combined with advanced MRI techniques such as myelin water imaging.

NCT03787446 Multiple Sclerosis
MeSH: Multiple Sclerosis Sclerosis


Primary Outcomes

Description: To show an increase in 11C-PBR28 binding in all sub-types of MS compared to healthy controls.

Measure: Whole Brain PBR28 binding

Time: January 2020

Secondary Outcomes

Description: To quantitatively measure the brain levels of water located within myelin

Measure: Myelin Water Imaging by MRI

Time: January 2020

Description: To correlate brain levels of inflammation measured by 11C-PBR28 with Retinal Nerve Fiber Layer (RNFL) thickness on Optical Coherence Tomography (OCT).

Measure: Optical Coherence Tomography

Time: January 2020

Description: To correlate brain levels of inflammation and myelin measured by PET with cognitive dysfunction in MS patients.

Measure: MS Spectroscopy

Time: January 2020

Time Perspective: Cross-Sectional

Cohort


There is one SNP

SNPs


1 rs6971

- Mixed affinity binder according to rs6971 TSPO polymorphism1.

Exclusion Criteria: - Low and high affinity binders according to rs6971 TSPO polymorphism - Subject pregnant or breastfeeding.

A separate pre-screening consent form will be issued for the TSPO rs6971 polymorphism and eGFR blood samples, a separate pre-screening step.

Eligible participants, according to their TSPO rs6971 polymorphism will be presented a separate study consent form to continue into the clinical trial.



HPO Nodes